1. Home
  2. NTHI vs SNFCA Comparison

NTHI vs SNFCA Comparison

Compare NTHI & SNFCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NTHI
  • SNFCA
  • Stock Information
  • Founded
  • NTHI 2008
  • SNFCA 1965
  • Country
  • NTHI United States
  • SNFCA United States
  • Employees
  • NTHI N/A
  • SNFCA N/A
  • Industry
  • NTHI Biotechnology: Pharmaceutical Preparations
  • SNFCA Finance: Consumer Services
  • Sector
  • NTHI Health Care
  • SNFCA Finance
  • Exchange
  • NTHI Nasdaq
  • SNFCA Nasdaq
  • Market Cap
  • NTHI 195.5M
  • SNFCA 234.1M
  • IPO Year
  • NTHI N/A
  • SNFCA N/A
  • Fundamental
  • Price
  • NTHI $6.40
  • SNFCA $7.88
  • Analyst Decision
  • NTHI
  • SNFCA
  • Analyst Count
  • NTHI 0
  • SNFCA 0
  • Target Price
  • NTHI N/A
  • SNFCA N/A
  • AVG Volume (30 Days)
  • NTHI 62.7K
  • SNFCA 21.2K
  • Earning Date
  • NTHI 11-14-2025
  • SNFCA 11-13-2025
  • Dividend Yield
  • NTHI N/A
  • SNFCA N/A
  • EPS Growth
  • NTHI N/A
  • SNFCA N/A
  • EPS
  • NTHI N/A
  • SNFCA 0.74
  • Revenue
  • NTHI $59,990.00
  • SNFCA $340,876,482.00
  • Revenue This Year
  • NTHI N/A
  • SNFCA N/A
  • Revenue Next Year
  • NTHI N/A
  • SNFCA N/A
  • P/E Ratio
  • NTHI N/A
  • SNFCA $10.63
  • Revenue Growth
  • NTHI N/A
  • SNFCA 3.25
  • 52 Week Low
  • NTHI $3.20
  • SNFCA $7.32
  • 52 Week High
  • NTHI $25.00
  • SNFCA $12.94
  • Technical
  • Relative Strength Index (RSI)
  • NTHI 31.38
  • SNFCA 44.57
  • Support Level
  • NTHI $8.93
  • SNFCA $7.70
  • Resistance Level
  • NTHI $9.57
  • SNFCA $8.39
  • Average True Range (ATR)
  • NTHI 1.15
  • SNFCA 0.23
  • MACD
  • NTHI -0.46
  • SNFCA -0.01
  • Stochastic Oscillator
  • NTHI 0.00
  • SNFCA 37.67

About NTHI NeOnc Technologies Holdings Inc. Common Stock

NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA).

About SNFCA Security National Financial Corporation

Security National Financial Corp is engaged in the life insurance, cemetery and mortuary, and mortgage loan businesses. The life insurance segment is engaged in the business of selling and servicing selected lines of life insurance, annuity products, and accident and health insurance. Its cemetery and mortuary segment consists of approximately seven mortuaries and five cemeteries in the state of Utah and a cemetery in the state of California. The mortgage loan segment originates and underwrites or otherwise purchases residential and commercial loans for new construction, existing homes, and real estate projects. Geographically, all the business activity is functioned through the region of the USA and it derives the majority of revenue from Mortgage segment.

Share on Social Networks: